Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 7/20 | 0.46 |
| ▸ | SLC22A2 | O15244 | 3/20 | 0.43 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.43 |
| ▸ | SLC22A3 | O75751 | 3/20 | 0.43 |
| ▸ | PLAU | P00749 | 2/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.37 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.35 |
| ▸ | HTR3B | O95264 | 3/20 | 0.35 |
| ▸ | HTR3A | P46098 | 3/20 | 0.35 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.35 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.35 |
| ▸ | NOS3 | P29474 | 5/20 | 0.33 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL782461 | 0.82 | NOS1 (0.46) | NOS1SLC22A2SLC22A1SLC22A3PLAU | |
| SCHEMBL19815146 | 0.69 | MAPT (0.53) | KCNN4NPC1MAPTRAB9AKMT2A | |
| SCHEMBL2257944 | 0.68 | MEN1 (0.46) | MEN1NPC1MAPTRAB9AKMT2A | |
| SCHEMBL27775063 | 0.68 | MEN1 (0.52) | MEN1NPC1MAPTRAB9AKMT2A | |
| SCHEMBL6683582 | 0.67 | KCNN4 (0.46) | SLC22A1KCNN4MEN1MAPTRAB9A | |
| SCHEMBL3576518 | 0.66 | NOS1 (0.47) | NOS1SLC22A2SLC22A1SLC22A3PLAU | |
| SCHEMBL8167395 | 0.64 | CES2 (0.41) | KCNN4NPC1MAPTRAB9AKMT2A | |
| SCHEMBL27641406 | 0.64 | KCNN4 (0.43) | KCNN4CYP2D6TDP1 | |
| Hydrochloric Acid SCHEMBL2860585 | 0.64 | NOS1 (1.00) | NOS1SLC22A2SLC22A1SLC22A3PLAU | |
| SCHEMBL785777 | 0.63 | KCNN4 (0.44) | KCNN4NPC1MAPTRAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121621-B1 | LXR AND FXR MODULATORS | EXELIXIS PATENT CO LLC (US) | 2014-05-07 | — | — | EP | disclosed |
| US-7998995-B2 | LXR and FXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998995-B2 | LXR and FXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998995-B2 | LXR and FXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100069367-A1 | LXR and FXR Modulators | EXELIXIS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069367-A1 | LXR and FXR Modulators | EXELIXIS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069367-A1 | LXR and FXR Modulators | EXELIXIS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| EP-2121621-A1 | LXR AND FXR MODULATORS | Exelixis, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008073825-A1 | LXR AND FXR MODULATORS | EXELIXIS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069367-A1 | LXR and FXR Modulators | NR1H3, NR1H2, NR1H4 | NOS1 2117/4885SLC22A2 1146/4885SLC22A1 829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.